Laboratory diagnosis of Legionella pneumophila

Legionella pneumophila is a gram-negative, aerobic, rod-shaped bacterium that causes a severe form of pneumonia called Legionnaires` disease. Legionnaires` disease is characterized by fever, cough, dyspnea, and chest pain, and can be complicated by multisystem organ failure and death. The mortality rate of Legionnaires` disease ranges from 5% to 30%, depending on the severity of the infection and the underlying health status of the patient.

Legionella pneumophila is found in natural and artificial water sources, such as lakes, rivers, hot springs, cooling towers, air conditioners, humidifiers, and fountains. The bacterium can survive and multiply in biofilms and amoebae that colonize these water systems. Humans can become infected by inhaling aerosols or droplets containing the bacteria, or by aspirating contaminated water. The incubation period of Legionnaires` disease is usually 2 to 10 days, but can be as long as 19 days.

The laboratory diagnosis of Legionella pneumophila is important for confirming the etiology of the disease, guiding the appropriate treatment, and preventing further outbreaks. However, the diagnosis can be challenging because of the low sensitivity and specificity of some methods, the limited availability and accessibility of some tests, and the variability in the clinical presentation and course of the disease.

The main methods for laboratory diagnosis of Legionella pneumophila are:

• Microscopy techniques for detection
• Culture methods for identification
• Antigen tests for rapid detection
• Serology for antibody detection
• Nucleic acid amplification for increased sensitivity

Each method has its own advantages and limitations, and they can be used in combination to increase the diagnostic accuracy and timeliness. In this article, we will review each method in detail and discuss their applications and implications for clinical practice.

The choice of specimen for laboratory diagnosis of Legionella pneumophila depends on the type and severity of the infection, as well as the availability and feasibility of the diagnostic methods. The most common specimens are respiratory secretions, such as sputum, bronchial aspirate or washings, which can be obtained by expectoration, bronchoscopy or tracheal intubation. Other specimens that may be useful are pleural fluid, lung biopsy or autopsy material, especially in cases of severe pneumonia or disseminated infection.

The quality and quantity of the specimen are important factors that affect the sensitivity and specificity of the diagnostic tests. Ideally, the specimen should be collected before the initiation of antibiotic therapy, as this may reduce the number of viable bacteria and interfere with culture and nucleic acid amplification methods. The specimen should also be collected as early as possible in the course of the infection, preferably within the first week of illness. The specimen should contain adequate amount of respiratory secretions and minimal contamination by saliva or oral flora.

The specimen should be transported to the laboratory as soon as possible after collection, preferably within 2 hours. If transport is delayed, the specimen should be refrigerated at 4°C or frozen at -70°C to preserve the viability of the bacteria. The specimen should be labeled with the patient`s name, identification number, date and time of collection, type of specimen and clinical diagnosis.

The specimen should be processed in a biosafety level 2 laboratory with appropriate precautions to avoid aerosol generation and exposure to infectious agents. The specimen should be homogenized and liquefied by adding an equal volume of sterile distilled water or 0.1% dithiothreitol (DTT) solution and vortexing for 15 seconds. The specimen should then be centrifuged at 3000 x g for 15 minutes to concentrate the bacteria and remove debris. The supernatant should be discarded and the pellet should be resuspended in 1 ml of sterile distilled water or phosphate-buffered saline (PBS) for further testing.

Depending on the type of specimen and the diagnostic method to be used, different pretreatment steps may be required to enhance the detection of Legionella pneumophila. For example, potentially contaminated material such as sputum or post-mortem material may be heated at 50°C for 30 minutes to diminish growth by less heat-stable respiratory tract organisms that may inhibit growth of legionellae in culture. Alternatively, selective decontamination agents such as N-acetyl-L-cysteine (NALC), sodium hydroxide (NaOH) or ethylenediaminetetraacetic acid (EDTA) may be added to the specimen to lyse or inhibit other bacteria and fungi without affecting legionellae. However, these methods may also reduce the viability and recovery of legionellae, so they should be used with caution and validated for each specimen type and diagnostic method.

The processed specimen should then be aliquoted into sterile tubes or containers for different diagnostic tests, such as microscopy, culture, antigen detection, serology or nucleic acid amplification. Each aliquot should be labeled with the same information as the original specimen and stored at appropriate temperature until testing.

Microscopy is a method of visualizing Legionella pneumophila bacteria in clinical specimens using different types of stains or antibodies. Microscopy can provide rapid and specific results, but it has some limitations in terms of sensitivity and availability.

One microscopy technique is the Gram stain, which is a common method of staining bacteria based on their cell wall structure. However, Legionella pneumophila bacteria stain poorly with Gram stain and are rarely recognized in clinical specimens. This is because they are small, intracellular bacteria that are often obscured by other respiratory tract flora or host cells.

Another microscopy technique is the Dieterle silver stain, which is a nonspecific method of staining bacteria with silver nitrate. This stain can highlight Legionella pneumophila bacteria in tissue specimens, such as lung biopsy or autopsy material, but it is not suitable for sputum specimens. The Dieterle silver stain also requires specialized equipment and expertise, and it may cross-react with other bacteria or fungi.

The most sensitive microscopy technique for detecting Legionella pneumophila bacteria in clinical specimens is the direct fluorescent antibody (DFA) test, which uses fluorescein-labeled antibodies that bind to specific antigens on the surface of the bacteria. The DFA test can be performed on sputum, bronchial aspirate or washings, or pleural fluid specimens. The DFA test can also use monoclonal or polyclonal antibodies that target different species or serotypes of Legionella pneumophila.

The advantages of the DFA test are that it can provide rapid and specific results, and it can detect low numbers of bacteria in clinical specimens. The disadvantages of the DFA test are that it requires fresh or frozen specimens, it may have false-positive reactions with polyclonal antibodies, and it may miss some infections caused by uncommon species or serotypes of Legionella pneumophila.

Because of the problems with the DFA test, microscopy has been replaced with antigen detection tests in most laboratories. Antigen detection tests are discussed in point 5 of this article.

Culture is the gold standard for the diagnosis of Legionella pneumophila infection. It allows for the isolation and identification of the causative agent, as well as the determination of its antimicrobial susceptibility and epidemiological typing. However, culture is also time-consuming, labor-intensive and requires special media and conditions.

The most commonly used medium for culturing Legionella pneumophila is Buffered Charcoal Yeast Extract (BCYE) agar, which contains cysteine and iron as essential growth factors for the bacteria. BCYE agar can be supplemented with antibiotics, such as polymyxin B, vancomycin and cycloheximide, to inhibit the growth of other respiratory flora. Alternatively, BCYE agar can be heated at 50°C for 30 minutes before inoculation to reduce the contamination by heat-sensitive organisms.

The specimens for culture should be collected from lower respiratory tract sources, such as sputum, bronchoalveolar lavage (BAL) fluid, lung tissue or pleural fluid. The specimens should be transported to the laboratory as soon as possible and stored at 4°C until processing. The specimens should be homogenized and centrifuged to concentrate the bacteria before inoculation onto BCYE agar plates. The plates should be incubated at 36°C in a humidified atmosphere with 2.5% carbon dioxide for up to 10 days.

The colonies of Legionella pneumophila on BCYE agar are usually small (3 to 4 mm in diameter), gray-white to blue-green, glistening, convex and circular. They may exhibit a cut-glass appearance under low magnification or fluoresce blue-white under ultraviolet light. The colonies should be confirmed by Gram stain, which shows poorly staining gram-negative rods that are often intracellular in phagocytes. The colonies should also be subcultured onto blood agar or cysteine-deficient medium to demonstrate their requirement for cysteine.

The identification of Legionella pneumophila can be further confirmed by using specific antisera in an immunofluorescence test or by using molecular methods, such as polymerase chain reaction (PCR) or gene sequencing. The serogrouping of Legionella pneumophila can be performed by using monoclonal antibodies in a slide agglutination test or by using PCR-based methods. The serogrouping is important for epidemiological purposes, as different serogroups may have different virulence and prevalence.

The advantages of culture are its high specificity, its ability to provide isolates for further characterization and its potential to detect all Legionella species and serogroups. However, the disadvantages of culture are its low sensitivity (10 to 80%), its long turnaround time (3 to 10 days) and its dependence on the quality of the specimen and the culture technique. Therefore, culture should be used in conjunction with other diagnostic methods, such as antigen detection or nucleic acid amplification, to increase the diagnostic yield and accuracy.

Antigen tests are methods that can detect the presence of Legionella antigens in urine and other body fluids. Antigens are molecules that trigger an immune response and can be used as markers of infection. Antigen tests are useful for rapid diagnosis of Legionella pneumophila infection, especially when culture or microscopy techniques are not available or reliable.

The most common antigen test for Legionella pneumophila is the enzyme immunoassay (EIA), which uses antibodies that bind to specific antigens and produce a color change or a signal that can be measured. EIA can detect Legionella antigen in urine samples within hours of onset of symptoms and can remain positive for several weeks after infection. However, EIA has some limitations, such as:

• It can only detect L. pneumophila serogroup 1, which accounts for about 80% of cases, but not other serogroups or species of Legionella.
• It can cross-react with other bacteria or substances in urine and cause false-positive results.
• It can have low sensitivity and miss some cases of infection, especially if the urine sample is diluted or contaminated.

Another antigen test for Legionella pneumophila is the immunochromatography test, which uses a strip of paper or plastic coated with antibodies that capture the antigens and produce a visible line or dot. Immunochromatography test is simpler and faster than EIA and can be performed at the point of care without specialized equipment. However, immunochromatography test also has some drawbacks, such as:

• It has lower sensitivity and specificity than EIA and may miss some cases or give false results.
• It may not detect low levels of antigen in urine samples.
• It may not be widely available or standardized.

Antigen tests are helpful for screening and confirming cases of Legionella pneumophila infection, but they should not be used alone for diagnosis. They should be combined with other methods, such as culture, microscopy, serology, or nucleic acid amplification, to provide a comprehensive and accurate diagnosis. Antigen tests can also be used for epidemiological purposes, such as outbreak investigation and surveillance.

Serology is the study of antibodies in blood serum. Antibodies are proteins produced by the immune system in response to foreign antigens, such as bacteria or viruses. Antibodies can help to identify the cause of an infection by binding to specific antigens and forming complexes that can be detected by various methods.

Serology can be used to diagnose Legionella pneumophila infection by measuring the level and type of antibodies against the bacterium in the patient`s serum. The most common method for serological testing is the indirect fluorescent antibody (IFA) test, which uses fluorescent-labeled anti-human antibodies to detect the presence of anti-Legionella antibodies in the serum. The IFA test can detect antibodies against different serogroups and species of Legionella, but it requires specialized equipment and trained personnel.

The advantages of serology are that it can provide retrospective confirmation of infection, it can detect cases caused by uncommon or unculturable strains of Legionella, and it can help to monitor the epidemiology and outbreak investigation of legionellosis. However, serology also has some limitations, such as:

• It requires paired serum samples collected at least two weeks apart to demonstrate a fourfold or greater rise in antibody titre, which is considered diagnostic of infection. A single high titre may be indicative but not conclusive of infection, as some healthy individuals may have high background titres due to previous exposure or cross-reactivity with other bacteria.
• It has low sensitivity and specificity, especially in the early stages of infection, as antibodies may take 8 to 10 days or longer to develop after the onset of symptoms. Some patients may not produce antibodies at all or only at low levels.
• It may not distinguish between current and past infections, as antibodies may persist for months or years after recovery or treatment.
• It may not reflect the severity or outcome of infection, as antibody levels may vary depending on the host immune response and other factors.

Therefore, serology should not be used as the sole method for diagnosing Legionella pneumophila infection, but rather as a complementary tool to other methods, such as culture, antigen detection, and nucleic acid amplification. Serology can also be useful for screening large populations or groups at risk of exposure to Legionella, such as travelers, hotel guests, or hospital patients. Serology can help to identify potential sources and modes of transmission of infection and to evaluate the effectiveness of preventive measures and interventions.

Nucleic acid amplification (NAA) is a molecular technique that can detect the genetic material of Legionella pneumophila in clinical specimens, such as respiratory secretions, urine, blood, or tissue. NAA methods include conventional and real-time polymerase chain reaction (PCR), which can amplify and measure the amount of Legionella DNA or RNA present in a sample.

NAA has several advantages over other diagnostic methods for Legionella pneumophila:

• It can provide rapid results, usually within a few hours, compared to several days for culture or antigen tests.
• It can detect Legionella pneumophila even when the bacteria are not viable or culturable, such as after antibiotic treatment or in environmental samples.
• It can identify the specific serogroup or strain of Legionella pneumophila, which can help in epidemiological investigations and outbreak control.
• It can detect Legionella pneumophila in specimens that have low bacterial load or are contaminated with other microorganisms, such as sputum or urine.
• It can detect other Legionella species that may not be detected by antigen tests or serology.

However, NAA also has some limitations and challenges:

• It requires specialized equipment and trained personnel, which may not be available in all laboratories or settings.
• It may be affected by inhibitors or contaminants in the specimens, which can reduce the sensitivity or specificity of the test.
• It may not distinguish between active infection and colonization or exposure to Legionella pneumophila, which can lead to false-positive results.
• It may not correlate well with clinical outcomes or response to treatment, as the presence of Legionella DNA or RNA does not necessarily reflect the viability or virulence of the bacteria.
• It may not be standardized or validated across different laboratories or platforms, which can affect the comparability and reproducibility of the results.

Therefore, NAA should be used as a complementary method to other diagnostic tests for Legionella pneumophila, and the results should be interpreted in the context of clinical and epidemiological data. NAA can be especially useful for confirming suspected cases of legionellosis, identifying the source of infection in outbreaks, and monitoring the effectiveness of environmental interventions.

Legionellosis is a serious infection caused by Legionella pneumophila and other related bacteria. It can manifest as a mild flu-like illness (Pontiac fever) or a severe pneumonia (Legionnaires` disease). The treatment of legionellosis depends on the severity of the symptoms, the underlying health conditions of the patient, and the susceptibility of the bacteria to antibiotics.

The mainstay of treatment for legionellosis is antibiotic therapy. The choice of antibiotic depends on several factors, such as the availability, cost, side effects, and efficacy of the drug. The most commonly used antibiotics for legionellosis are:

• Macrolides: These are a group of antibiotics that inhibit bacterial protein synthesis. They include erythromycin, azithromycin, clarithromycin, and telithromycin. Macrolides are effective against most strains of Legionella pneumophila and have good penetration into lung tissue. They are usually given orally or intravenously for 7 to 21 days, depending on the severity of the infection and the response to treatment. Macrolides are generally well tolerated, but they may cause gastrointestinal upset, allergic reactions, liver toxicity, or cardiac arrhythmias in some patients.
• Fluoroquinolones: These are a group of antibiotics that interfere with bacterial DNA replication. They include ciprofloxacin, levofloxacin, moxifloxacin, and gemifloxacin. Fluoroquinolones are also effective against most strains of Legionella pneumophila and have excellent penetration into lung tissue. They are usually given orally or intravenously for 7 to 14 days, depending on the severity of the infection and the response to treatment. Fluoroquinolones are generally well tolerated, but they may cause gastrointestinal upset, allergic reactions, tendon rupture, nerve damage, or QT prolongation in some patients.
• Tetracyclines: These are a group of antibiotics that inhibit bacterial protein synthesis. They include doxycycline and minocycline. Tetracyclines are effective against most strains of Legionella pneumophila and have good penetration into lung tissue. They are usually given orally for 14 to 21 days, depending on the severity of the infection and the response to treatment. Tetracyclines are generally well tolerated, but they may cause gastrointestinal upset, allergic reactions, photosensitivity, tooth discoloration, or esophageal ulceration in some patients.

In some cases, combination therapy with two or more antibiotics may be required to achieve better clinical outcomes or to overcome antibiotic resistance. For example, rifampin (a bactericidal antibiotic that inhibits bacterial RNA synthesis) may be added to macrolides or fluoroquinolones in severe cases of legionellosis or in patients who fail to respond to monotherapy. However, rifampin may interact with other drugs and cause liver toxicity or hematologic abnormalities in some patients.

In addition to antibiotic therapy, supportive care is also important for the management of legionellosis. This may include:

• Fluid and electrolyte replacement: Patients with legionellosis may lose fluids and electrolytes due to fever, sweating, vomiting, or diarrhea. Therefore, adequate hydration and electrolyte balance should be maintained by oral or intravenous fluids.
• Oxygen therapy: Patients with legionellosis may develop hypoxia (low oxygen levels in the blood) due to impaired gas exchange in the lungs. Therefore, supplemental oxygen should be administered by nasal cannula or mask to improve oxygenation and prevent organ damage.
• Ventilatory support: Patients with severe legionellosis may develop respiratory failure (inability to breathe adequately) due to severe lung inflammation or damage. Therefore, mechanical ventilation (artificial breathing) may be required to assist breathing and maintain adequate oxygenation and carbon dioxide elimination.
• Antipyretics: Patients with legionellosis may develop high fever (above 38°C or 100.4°F) due to the infection. Therefore, antipyretics (fever-reducing drugs) such as acetaminophen or ibuprofen may be given to lower the body temperature and reduce discomfort.
• Analgesics: Patients with legionellosis may experience pain due to headache, muscle ache, chest pain, or abdominal pain. Therefore, analgesics (pain-relieving drugs) such as acetaminophen or ibuprofen may be given to reduce pain and improve comfort.

The prognosis (outcome) of legionellosis depends on several factors, such as the severity of the infection, the underlying health conditions of the patient, and the timeliness and appropriateness of treatment. The mortality (death) rate of legionellosis ranges from 5% to 30%, depending on these factors. Early diagnosis and prompt treatment can improve the survival and recovery of patients with legionellosis.

We are Compiling this Section. Thanks for your understanding.